Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 55

1.

Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease.

Byrne LM, Rodrigues FB, Johnson EB, Wijeratne PA, De Vita E, Alexander DC, Palermo G, Czech C, Schobel S, Scahill RI, Heslegrave A, Zetterberg H, Wild EJ.

Sci Transl Med. 2018 Sep 12;10(458). pii: eaat7108. doi: 10.1126/scitranslmed.aat7108.

PMID:
30209243
2.

Huntington's Disease Clinical Trials Corner: August 2018.

Rodrigues FB, Wild EJ.

J Huntingtons Dis. 2018;7(3):279-286. doi: 10.3233/JHD-189003.

3.

Physician perception versus true efficacy of tetrabenazine for Huntington's disease.

Rodrigues FB, Ferreira JJ, Wild EJ.

Curr Med Res Opin. 2018 Sep;34(9):1537-1538. doi: 10.1080/03007995.2018.1490703. Epub 2018 Jul 19. No abstract available.

PMID:
29920125
4.

Biofluid Biomarkers in Huntington's Disease.

Rodrigues FB, Byrne LM, Wild EJ.

Methods Mol Biol. 2018;1780:329-396. doi: 10.1007/978-1-4939-7825-0_17.

PMID:
29856027
5.

Perinatal insults and neurodevelopmental disorders may impact Huntington's disease age of diagnosis.

Barkhuizen M, Rodrigues FB, Anderson DG, Winkens B; REGISTRY Investigators of the European Huntington's Disease Network, Wild EJ, Kramer BW, Gavilanes AWD.

Parkinsonism Relat Disord. 2018 May 18. pii: S1353-8020(18)30246-3. doi: 10.1016/j.parkreldis.2018.05.016. [Epub ahead of print]

6.

Cerebrospinal fluid neurogranin and TREM2 in Huntington's disease.

Byrne LM, Rodrigues FB, Johnson EB, De Vita E, Blennow K, Scahill R, Zetterberg H, Heslegrave A, Wild EJ.

Sci Rep. 2018 Mar 9;8(1):4260. doi: 10.1038/s41598-018-21788-x.

7.

Huntington’s Disease Clinical Trials Corner: February 2018

Rodrigues FB, Wild EJ.

J Huntingtons Dis. 2018;7(1):89-98. doi: 10.3233/JHD-189001.

8.

Neurofilament light protein in blood predicts regional atrophy in Huntington disease.

Johnson EB, Byrne LM, Gregory S, Rodrigues FB, Blennow K, Durr A, Leavitt BR, Roos RA, Zetterberg H, Tabrizi SJ, Scahill RI, Wild EJ; TRACK-HD Study Group.

Neurology. 2018 Feb 20;90(8):e717-e723. doi: 10.1212/WNL.0000000000005005. Epub 2018 Jan 24.

9.

Quantification of huntingtin protein species in Huntington's disease patient leukocytes using optimised electrochemiluminescence immunoassays.

Hensman Moss DJ, Robertson N, Farmer R, Scahill RI, Haider S, Tessari MA, Flynn G, Fischer DF, Wild EJ, Macdonald D, Tabrizi SJ.

PLoS One. 2017 Dec 22;12(12):e0189891. doi: 10.1371/journal.pone.0189891. eCollection 2017.

10.

Meta-research metrics matter: letter regarding article "indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease".

Rodrigues FB, Duarte GS, Costa J, Ferreira JJ, Wild EJ.

J Clin Mov Disord. 2017 Nov 22;4:19. doi: 10.1186/s40734-017-0067-x. eCollection 2017.

11.

Validation of Ultrasensitive Mutant Huntingtin Detection in Human Cerebrospinal Fluid by Single Molecule Counting Immunoassay.

Fodale V, Boggio R, Daldin M, Cariulo C, Spiezia MC, Byrne LM, Leavitt BR, Wild EJ, Macdonald D, Weiss A, Bresciani A.

J Huntingtons Dis. 2017;6(4):349-361. doi: 10.3233/JHD-170269.

12.

Neurofilament light protein in CSF and blood is associated with neurodegeneration and disease severity in Huntington's disease R6/2 mice.

Soylu-Kucharz R, Sandelius Å, Sjögren M, Blennow K, Wild EJ, Zetterberg H, Björkqvist M.

Sci Rep. 2017 Oct 26;7(1):14114. doi: 10.1038/s41598-017-14179-1.

13.

Clinical Trials Corner: September 2017.

Rodrigues FB, Wild EJ.

J Huntingtons Dis. 2017;6(3):255-263. doi: 10.3233/JHD-170262. Review.

14.

Therapies targeting DNA and RNA in Huntington's disease.

Wild EJ, Tabrizi SJ.

Lancet Neurol. 2017 Oct;16(10):837-847. doi: 10.1016/S1474-4422(17)30280-6. Epub 2017 Sep 12. Review. Erratum in: Lancet Neurol. 2017 Dec;16(12 ):954.

15.

Tetrabenazine Versus Deutetrabenazine for Huntington's Disease: Twins or Distant Cousins?

Rodrigues FB, Duarte GS, Costa J, Ferreira JJ, Wild EJ.

Mov Disord Clin Pract. 2017 Jul-Aug;4(4):582-585. doi: 10.1002/mdc3.12483. Epub 2017 Mar 29.

16.

Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis.

Byrne LM, Rodrigues FB, Blennow K, Durr A, Leavitt BR, Roos RAC, Scahill RI, Tabrizi SJ, Zetterberg H, Langbehn D, Wild EJ.

Lancet Neurol. 2017 Aug;16(8):601-609. doi: 10.1016/S1474-4422(17)30124-2. Epub 2017 Jun 7. Erratum in: Lancet Neurol. 2017 Sep;16(9):683.

17.

Ghost Pills: A Case Report.

Salanio DM, Taylor R, Stanton JED, Wild EJ.

Ann Intern Med. 2017 Apr 18;166(8):609. doi: 10.7326/L16-0376. Epub 2017 Apr 4. No abstract available.

PMID:
28384661
18.

Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntington's Disease.

Rodrigues FB, Byrne LM, McColgan P, Robertson N, Tabrizi SJ, Zetterberg H, Wild EJ.

PLoS One. 2016 Sep 22;11(9):e0163479. doi: 10.1371/journal.pone.0163479. eCollection 2016.

19.

Huntington's Disease: The Most Curable Incurable Brain Disorder?

Wild EJ.

EBioMedicine. 2016 Jun;8:3-4. doi: 10.1016/j.ebiom.2016.05.023. Epub 2016 May 19. No abstract available.

20.

George Huntington: a legacy of inquiry, empathy and hope.

Wexler A, Wild EJ, Tabrizi SJ.

Brain. 2016 Aug;139(Pt 8):2326-33. doi: 10.1093/brain/aww165. Epub 2016 Jul 14. No abstract available.

Supplemental Content

Loading ...
Support Center